3,655 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Dohj LLC

Dohj LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,655 shares of the medical research company’s stock, valued at approximately $953,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the third quarter worth $29,000. Matrix Trust Co bought a new position in shares of Amgen during the third quarter worth $36,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen in the 4th quarter valued at $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the 3rd quarter valued at $56,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $285.42 on Friday. The company has a fifty day moving average price of $271.06 and a two-hundred day moving average price of $304.53. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market cap of $153.42 billion, a P/E ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the business posted $4.96 EPS. As a group, equities analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.34%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wolfe Research started coverage on Amgen in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Bank of America reiterated an “underperform” rating and set a $256.00 price objective on shares of Amgen in a report on Tuesday, December 10th. Royal Bank of Canada reissued an “outperform” rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Barclays lifted their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Citigroup reduced their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a report on Tuesday. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.